Navigation Links
AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
Date:12/7/2009

Evaluable 6.4 months 25 months Patients 95% CI (5.3, 7.1) 95% CI (15.5, NR) (n=73) ------------------------------------------------------------------------- NR = Not Reached * Median PFS and median TTP were identical, as no patient deaths occurred prior to progression. ** Kaplan Meier methodology was used to determine overall survival figures.

Of particular interest was the comparison of evaluable patients who were previously refractory and the patients who were relapsed to a bortezomib-based regimen.

    Median PFS and OS for bortezomib relapsed vs. refractory were as follows:

    -------------------------------------------------------------------------
    Bortezomib Relapsed
    vs. Refractory              Median PFS*         Median OS**
    -------------------------------------------------------------------------
    Bortezomib Relapsed         8.8 months            Not Reached at
    (n=20)           95% CI (6.3, 11.2)    38+ months  95% CI
                                                      (25, NR)
    -------------------------------------------------------------------------
    Bortezomib Refractory       5.7 months            22.5 months
    (n=53)           95% CI (4.3, 6.4)     95% CI (12.3, NR)
    -------------------------------------------------------------------------

    * Median PFS and median TTP were identical, as no patient deaths
    occurred prior to progression.
    ** Kaplan Meier methodology was used to determine overall survival
    figures.

No unexpected adverse events have been observed. Toxicities were manageable with supportive care.

"We congratulate our partner Keryx and their principle investigators Dr. Richardson and Dr. Anderson for the encouraging results for perifosine in multiple myeloma which further demonstrate perifosine's potential as a novel treatment for this indication. We now look for
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Barnhardt Manufacturing Company has earned ... Organic Cotton . The USDA Certified Biobased Product Label ... meets or exceeds levels set by USDA. Biobased products ... in significant part of agricultural, forestry, or marine ingredients. ... to be immediately identified as a USDA certified BioPreferred ...
(Date:9/18/2014)... Bipartisan passage this week by the ... stimulate development and commercialization of new technologies and promote ... of SPIE, the international society for optics and ... Innovation (RAMI) Act, now moves to the full Senate ... are optimistic that it will win passage there as ...
(Date:9/18/2014)...  Health Enhancement Products, Inc. (OTCQB: HEPI), a ... and metabolic processes, is pleased to announce the addition of ... Nola E. Masterson , a California ... September 17, 2014. "We,re very pleased and ... states Andrew Dahl , President and CEO. "She joins ...
(Date:9/18/2014)... -- Research and Markets has announced ... Report 2014" report to their offering. ... is a professional and in-depth study on the ... The report provides a basic overview of ... chain structure. The N-acetylcysteine market analysis is provided ...
Breaking Biology Technology:Barnhardt Manufacturing Company Earns USDA Certified Biobased Product Certification and Label for Organic Cotton 2House passage of high-tech manufacturing bill is move toward stronger economy, say SPIE leaders 2House passage of high-tech manufacturing bill is move toward stronger economy, say SPIE leaders 3Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2Global N-acetylcysteine Industry Report 2014 2
... LIBREVILLE, Gabon, December 2 ... Africa: Everyone,s Problem and Heritage" , ... June 2010 the,Gabonese Republic is hosting an international conference ... in Africa. The,conference will be attended by government and ...
... , ... an event bringing together the leaders in technology development ... announced the December 11th deadline for technology abstracts and ... World, in association with the Nano Science and Technology ...
... , SINGAPORE, Dec. 2 S*BIO Pte Ltd today ... at The American Society of Hematology 51st Annual Meeting and ... the clinical results from the Phase 1 dose-escalation trial of ... dose levels ranging from 100 to 600 mg. These doses ...
Cached Biology Technology:Libreville International Conference 2-3 June 2010 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5
(Date:9/18/2014)... tonight at the third annual Golden Goose Award ceremony ... infants and in paving the way for the telecommunications ... by the National Science Foundation, the National Institutes of ... honored at a ceremony at the Library of Congress ... Congress will be on hand to help present their ...
(Date:9/18/2014)... are too stressed they are often grouchy, grumpy, nasty, ... (BMI) at EPFL have just highlighted a fundamental synaptic ... the loss of social skills and cognitive impairment. When ... molecule in the brain. This was revealed by a ... Carmen Sandi,s team went to look for answers in ...
(Date:9/18/2014)... their entire lives nestling in the protective tentacles of ... they sometimes travel hundreds of kilometres across the open ... fish has been predicted, this is the first time ... populations has been observed. , Dr Steve Simpson, Senior ... University of Exeter, and colleagues from the Australian Research ...
Breaking Biology News(10 mins):3rd annual Golden Goose award ceremony honors 8 researchers; Unusual work had big results 2How stress tears us apart 2Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3
... the human gut adaptively shifts more than a quarter ... diet changes from sugar to complex carbohydrates. , This ... survive rapidly changing nutrient conditions but also helps maintain ... microbial society, according to researchers at Washington University School ...
... Inc. (Nasdaq: NGEN), developer of advanced diagnostic products, announced ... "Multiplexed Active Biologic Array" by the U.S. Patent and ... of addressing one or more electrodes (or "test sites") ... patent also covers a method for storing the value ...
... owners because of their vibrant colors. But those colors may ... For more than a century, biochemists have known that parrots ... of plumage colors, but their biochemical identity has remained elusive. ... behind the colors of parrots, describing on a molecular level ...
Cached Biology News:Highly adaptable genome in gut bacterium key to intestinal health 2Highly adaptable genome in gut bacterium key to intestinal health 3Nanogen Issued Patent for Electronic Microarray With Memory 2Transport System Smuggles Medicines Into Brain 2Transport System Smuggles Medicines Into Brain 3
... Odyssey images are easily imported for data analysis , ... ... Extensive background and signal options to optimize, ... results , ...
... UltraPure Agarose and SYBR Safe DNA Gel Stain ... Saves money versus buying these same products separately ... alternative to ethidium bromide ... Agarose resolves DNA and RNA fragments from 100 bp ...
... E.Coli glycerol stocks contained in standard 96-well ... clones with approximately 5,000 clones per plate. ... plate well, the corresponding subplate is screened ... the positive well(s). Cells from a positive ...
... ml per liter of urine will give a ... BMD dipstick. ,Certification: The Donors are of ... to be NEGATIVE for HbsAg, HCV, HIV-1 & ... FDA methods. THIS MATERIAL IS SOLD FOR IN-VITRO ...
Biology Products: